Speaker Profile

Ph.D., CEO, Eutropics Pharmaceuticals

Biography
Michael Cardone leads Eutropics’ scientific efforts to achieve corporate milestones. The company develops novel predictive diagnostic tools for personalized medicine. The new platform measures cellular mechanisms that regulate apoptosis. This platform is providing compositions and methods for assessing therapeutic approaches for blood and solid cancers and providing personalized treatments for individual patients. His experience includes 20 years of scientific and business management at early to mid-stage biotech companies. Prior to Eutropics, he was a scientific co-founder of publicly traded Merrimack Pharmaceuticals, a Cambridge, MA-based company where he worked with the starting team to develop the oncology program. Prior to this, he worked at MIT developing tools for small molecule drug target identification and validation. He received a Ph.D. in cell biology at UCSF and completed post-doctoral studies in apoptosis signaling at the Burnham Institute in La Jolla, CA.

Talk
Prediction of Tumor Cell Response to Therapy
Eutropics' unique panel of antibodies, “PRIMABs”, enable detection of tumor cell mitochondrial priming, a key determinant of cancer responsiveness to treatments. The presence (or absence) of the critical pro-survival : pro-apoptotic protein complexes, is used as a predictive biomarker for personalized medicine. Such reagents have hitherto not been available.


 Session Abstract – PMWC 2022 Silicon Valley


Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.

Sessions:

  • 4th Generation Sequencing Technologies & Genome Mapping Systems
    - Barrett Bready, Nabsys
    - Alka Chaubey, Bionano Genomics
  • Long-Read Sequencing Technologies
    - Steve Turner, PacBio
  • Single Cell Genomics
    - Michael Schnall-Levin, 10x Genomics
  • Spatial Transcriptomics
    - Jason T. Gammack, Resolve Biosciences
  • Pathogen Identification
    Session Chair: Charles Chiu, UCSF
    - Todd Dickinson, Arc Bio
    - Philip Stevens, Noscendo
  • ML/AI for Diagnosis & Prognosis
    - Amrie Grammer, Ampel BioSolutions
  • Modern Technologies for Pathogen Identification + AI
    Session Chair: Sivan Bercovici, Karius Dx
  • Proteogenomics
    - Nigel Beard, Encodia
  • Advances Proteomics - Stratifying Cardiovascular Risk to Decrease Cost of Care
    Session Chair: Roy Smythe, SomaLogic
    - Matthias Kleinz, UPMC
  • Leveraging Immune System Diagnostics to Improve Disease Outcomes
    Session Chair: Kathy Kamath, Serimmune, Inc
    - Millennia Lytle, Mymee
    - Noah Nasser, Serimmune, Inc
  • Evolving Alzheimer’s Disease Therapeutics with Neuro Diagnostic Therapies
    Session Chair: Kevin Hrusovsky, Quanterix
    - Charlotte Teunissen, Amsterdam UMC
    - Henrik Zetterberg, University of Gothenburg
    - Nicholas Ashton, University of Gothenburg
  • PMWC Showcase (NCI)
    - Michael Cardone, Eutropics Pharmaceuticals
    - Robert Meltzer, Fluent BioSciences
    - Cynthia Taylor Lawley, Olink Proteomics
    - Brian McKelligon, Akoya Biosciences